​

Replimune Group (REPL) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

REPL Stock Forecast

Replimune Group (REPL) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $25.50, with a high of $43.00 and a low of $13.00. This represents a 325.71% increase from the last price of $5.99.

$5 $13 $21 $29 $37 $45 High: $43 Avg: $25.5 Low: $13 Last Closed Price: $5.99

REPL Stock Rating

Replimune Group stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (60.00%), 5 Hold (33.33%), 1 Sell (6.67%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 1 5 9 Strong Sell Sell Hold Buy Strong Buy

REPL Price Target Upside V Benchmarks

TypeNameUpside
StockReplimune Group325.71%
SectorHealthcare Stocks 13.55%
IndustryBiotech Stocks 49.00%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$23.00
Last Closing Price$5.99$5.99$5.99
Upside/Downside--283.97%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 25-261-9
Aug, 25-261-9
Jul, 2545---9
Jun, 2553---8
May, 2553---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 22, 2025Evan SeigermanBMO Capital$27.00$13.09106.26%350.75%
Dec 03, 2024Roger SongJefferies$19.00$14.4831.22%217.20%
Jun 07, 2024Robert BurnsH.C. Wainwright$17.00$7.11139.10%183.81%
Jun 04, 2024Peter LawsonBarclays$13.00$5.37142.09%117.03%
May 17, 2024Evan SeigermanBMO Capital$14.00$6.85104.38%133.72%
Dec 12, 2022BMO Capital$70.00$25.00180.00%1068.61%
Dec 07, 2022Leerink Partners$34.00$23.0947.25%467.61%
Oct 03, 2022Leerink Partners$30.00$17.2773.71%400.83%
Aug 17, 2022Piper Sandler$43.00$20.62108.54%617.86%
Aug 05, 2022Leerink Partners$37.00$20.3781.64%517.70%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 30, 2025Cantor FitzgeraldOverweightupgrade
Jan 22, 2025BMO CapitalOutperformOutperformhold
Dec 03, 2024JefferiesBuyBuyhold
Nov 22, 2024BMO CapitalOutperformOutperformhold
Sep 10, 2024BMO CapitalOutperformOutperformhold
Sep 10, 2024H.C. WainwrightBuyBuyhold
Aug 08, 2024Rodman & RenshawBuyinitialise
Jun 07, 2024BMO CapitalOutperformOutperformhold
Jun 07, 2024H.C. WainwrightBuyBuyhold
Jun 04, 2024BarclaysOverweightOverweighthold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-3.24-----
Avg Forecast$-3.05$-2.74$-2.40$-2.10$-1.19$0.29
High Forecast$-2.93$-2.68$-2.30$-1.77$0.26$0.98
Low Forecast$-3.25$-2.79$-2.53$-2.75$-4.08$-0.06
Surprise %6.23%-----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported------
Avg Forecast-$8.75M$53.56M$135.57M$333.85M$606.00M
High Forecast-$25.12M$160.55M$389.25M$958.60M$1.74B
Low Forecast-$527.05K$3.98M$8.17M$20.11M$36.51M
Surprise %------

Net Income Forecast

$-300M $-220M $-140M $-60M $20M $100M Mar 24 Mar 25 Mar 26 Mar 27 Mar 28 Mar 29
Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29
Reported$-215.79M-----
Avg Forecast$-209.96M$-181.99M$-161.00M$-150.38M$-79.22M$18.97M
High Forecast$-195.05M$-178.51M$-153.27M$-117.88M$17.56M$65.13M
Low Forecast$-216.10M$-185.47M$-168.73M$-182.87M$-271.93M$-4.21M
Surprise %2.78%-----

REPL Forecast FAQ

Is Replimune Group stock a buy?

Replimune Group stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 5 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Replimune Group is a favorable investment for most analysts.

What is Replimune Group's price target?

Replimune Group's price target, set by 15 Wall Street analysts, averages $25.5 over the next 12 months. The price target range spans from $13 at the low end to $43 at the high end, suggesting a potential 325.71% change from the previous closing price of $5.99.

How does Replimune Group stock forecast compare to its benchmarks?

Replimune Group's stock forecast shows a 325.71% upside, outperforming the average forecast for the healthcare stocks sector (13.55%) and outperforming the biotech stocks industry (49.00%).

What is the breakdown of analyst ratings for Replimune Group over the past three months?

  • September 2025: 0% Strong Buy, 22.22% Buy, 66.67% Hold, 11.11% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 22.22% Buy, 66.67% Hold, 11.11% Sell, 0% Strong Sell.
  • July 2025: 44.44% Strong Buy, 55.56% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Replimune Group’s EPS forecast?

Replimune Group's average annual EPS forecast for its fiscal year ending in March 2025 is $-2.74, marking a -15.43% decrease from the reported $-3.24 in 2024. Estimates for the following years are $-2.4 in 2026, $-2.1 in 2027, $-1.19 in 2028, and $0.29 in 2029.

What is Replimune Group’s revenue forecast?

Replimune Group's average annual revenue forecast for its fiscal year ending in March 2025 is $8.75M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $53.56M, followed by $135.57M for 2027, $333.85M for 2028, and $606M for 2029.

What is Replimune Group’s net income forecast?

Replimune Group's net income forecast for the fiscal year ending in March 2025 stands at $-182M, representing a -15.66% decrease from the reported $-216M in 2024. Projections indicate $-161M in 2026, $-150M in 2027, $-79.218M in 2028, and $18.97M in 2029.